Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer
Androgen receptor pathway inhibitors (ARPI) and polyadenosine diphosphate-ribose inhibitors (PARPi) are part of the standard of care in patients with metastatic castration-resistant prostate cancer (mCRPC). There is biological evidence that the association of ARPI and PARPi could have a synergistic effect; therefore, several ongoing clinical trials are investigating the efficacy of this combination with preliminary results that are not perfectly concordant in identifying patients who can obtain the most benefit from this therapeutic option. The purpose of this review is to describe the PARPi mechanisms of action and to analyze the biological mechanisms behind the interplay between the androgen receptor and the PARPi system to better understand the rationale of the ARPI + PARPi combinations. Furthermore, we will summarize the preliminary results of the ongoing studies on these combinations, trying to understand in which patients to apply. Finally, we will discuss the clinical implications of this combination and its possible future perspectives.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2023 |
|---|---|
| Erschienen: |
2023 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:25 |
|---|---|
| Enthalten in: |
International journal of molecular sciences - 25(2023), 1 vom: 20. Dez. |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Calabrese, Mariangela [VerfasserIn] |
|---|
| Links: |
|---|
| Anmerkungen: |
Date Completed 12.01.2024 Date Revised 13.01.2024 published: Electronic Citation Status MEDLINE |
|---|
| doi: |
10.3390/ijms25010078 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM366938347 |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM366938347 | ||
| 003 | DE-627 | ||
| 005 | 20240114234902.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240114s2023 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.3390/ijms25010078 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1258.xml |
| 035 | |a (DE-627)NLM366938347 | ||
| 035 | |a (NLM)38203248 | ||
| 035 | |a (PII)78 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Calabrese, Mariangela |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Synthetic Lethality by Co-Inhibition of Androgen Receptor and Polyadenosine Diphosphate-Ribose in Metastatic Prostate Cancer |
| 264 | 1 | |c 2023 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Completed 12.01.2024 | ||
| 500 | |a Date Revised 13.01.2024 | ||
| 500 | |a published: Electronic | ||
| 500 | |a Citation Status MEDLINE | ||
| 520 | |a Androgen receptor pathway inhibitors (ARPI) and polyadenosine diphosphate-ribose inhibitors (PARPi) are part of the standard of care in patients with metastatic castration-resistant prostate cancer (mCRPC). There is biological evidence that the association of ARPI and PARPi could have a synergistic effect; therefore, several ongoing clinical trials are investigating the efficacy of this combination with preliminary results that are not perfectly concordant in identifying patients who can obtain the most benefit from this therapeutic option. The purpose of this review is to describe the PARPi mechanisms of action and to analyze the biological mechanisms behind the interplay between the androgen receptor and the PARPi system to better understand the rationale of the ARPI + PARPi combinations. Furthermore, we will summarize the preliminary results of the ongoing studies on these combinations, trying to understand in which patients to apply. Finally, we will discuss the clinical implications of this combination and its possible future perspectives | ||
| 650 | 4 | |a Journal Article | |
| 650 | 4 | |a Review | |
| 650 | 4 | |a BRCA mutation | |
| 650 | 4 | |a PARP inhibitors | |
| 650 | 4 | |a androgen receptor | |
| 650 | 4 | |a androgen receptor pathway inhibitor | |
| 650 | 4 | |a homologous recombination repair | |
| 650 | 4 | |a prostate cancer | |
| 650 | 4 | |a synthetic lethality | |
| 650 | 7 | |a Receptors, Androgen |2 NLM | |
| 650 | 7 | |a polyadenosine |2 NLM | |
| 650 | 7 | |a 30143-02-3 |2 NLM | |
| 650 | 7 | |a Diphosphates |2 NLM | |
| 650 | 7 | |a Ribose |2 NLM | |
| 650 | 7 | |a 681HV46001 |2 NLM | |
| 650 | 7 | |a Androgen Receptor Antagonists |2 NLM | |
| 650 | 7 | |a Adenosine |2 NLM | |
| 650 | 7 | |a K72T3FS567 |2 NLM | |
| 650 | 7 | |a Polymers |2 NLM | |
| 700 | 1 | |a Saporita, Isabella |e verfasserin |4 aut | |
| 700 | 1 | |a Turco, Fabio |e verfasserin |4 aut | |
| 700 | 1 | |a Gillessen, Silke |e verfasserin |4 aut | |
| 700 | 1 | |a Castro, Elena |e verfasserin |4 aut | |
| 700 | 1 | |a Vogl, Ursula Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Di Stefano, Rosario Francesco |e verfasserin |4 aut | |
| 700 | 1 | |a Carfì, Federica Maria |e verfasserin |4 aut | |
| 700 | 1 | |a Poletto, Stefano |e verfasserin |4 aut | |
| 700 | 1 | |a Farinea, Giovanni |e verfasserin |4 aut | |
| 700 | 1 | |a Tucci, Marcello |e verfasserin |4 aut | |
| 700 | 1 | |a Buttigliero, Consuelo |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t International journal of molecular sciences |d 2008 |g 25(2023), 1 vom: 20. Dez. |w (DE-627)NLM185552161 |x 1422-0067 |7 nnns |
| 773 | 1 | 8 | |g volume:25 |g year:2023 |g number:1 |g day:20 |g month:12 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.3390/ijms25010078 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 25 |j 2023 |e 1 |b 20 |c 12 | ||